Articles of association with latest amendments as of March 27, 2009
April 14, 2009 05:27 ET
|
ALK Abello
ALK-Abelló A/S - Articles of association with latest amendments as of March 27,
2009
...
Selskabsvedtægter med seneste ændringer pr. 27. marts 2009
April 14, 2009 05:27 ET
|
ALK Abello
ALK-Abelló A/S - Selskabsvedtægter med seneste ændringer pr. 27. marts 2009
...
Generalforsamlingsforløb i ALK-Abelló A/S den 27. marts 2009
March 27, 2009 12:21 ET
|
ALK Abello
På den ordinære generalforsamling i ALK-Abelló A/S den 27. marts 2009 skete
følgende:
- Årsrapporten for 2008 blev godkendt, og der blev meddelt decharge for
direktion og bestyrelse.
- Der...
Report on the Annual General Meeting of ALK-Abelló A/S held on March 27, 2009
March 27, 2009 12:21 ET
|
ALK Abello
The AGM of ALK-Abelló A/S held on March 27, 2009 transacted the following
business:
- Adoption of the annual report 2008 and discharge of the Board of Management
and the Board of Directors....
Ordinær generalforsamling i ALK-Abelló A/S den 27. marts 2009
March 05, 2009 10:08 ET
|
ALK Abello
Ordinær generalforsamling i ALK-Abelló A/S finder sted fredag den 27. marts
2009 kl. 16.00 i Den Sorte Diamant, Søren Kierkegaards Plads 1, 1221 København
K i henhold til vedhæftede indkaldelse med...
Annual General Meeting in ALK-Abelló A/S on March 27, 2009
March 05, 2009 10:08 ET
|
ALK Abello
The annual general meeting of ALK-Abelló A/S will take place on Friday, March
27, 2009 at 4.00 p.m. at Den Sorte Diamant, Søren Kierkegaards Plads 1 in
Copenhagen. The agenda of the meeting...
ALK og Novozymes indgår aftale om fremtidige allergivacciner
February 23, 2009 04:36 ET
|
ALK Abello
ALK og Novozymes har i dag underskrevet en aftale om produktion af industrielt
fremstillede allergener, også kaldet rekombinante allergener, til brug i ALKs
fremtidige tabletbaserede...
ALK and Novozymes enter collaboration on future allergy vaccines
February 23, 2009 04:36 ET
|
ALK Abello
Today, ALK and Novozymes have signed an agreement regarding industrially
produced allergens, also called recombinant allergens, for use in ALK's future
allergy immunotherapy tablets.
Under the...
ALK announces annual report for 2008
February 19, 2009 07:58 ET
|
ALK Abello
For ALK, 2008 was a good year with breakthrough research results and
satisfactory financial results. ALK met its financial forecast and generated a
five-fold increase of the underlying operating...
ALK offentliggør årsrapport for 2008
February 19, 2009 07:58 ET
|
ALK Abello
For ALK blev 2008 et godt år med banebrydende forskningsresultater og
tilfredsstillende økonomiske resultater. ALK indfriede sine økonomiske
forventninger og realiserede en femdobling af den...